Cardiogen | Buy Online | Heart Bioregulator Guide

A 74-year-old man walks into a Russian gerontology clinic with a heart that his cardiologist has described, diplomatically, as "showing its age." Reduced ejection fraction, chronic fatigue, the kind of arrhythmia that makes sleeping feel like a gamble. Twelve weeks later, his ECG has normalized in two key parameters, his exercise tolerance has measurably improved, and his cardiologist is asking what changed. The answer is a three-amino-acid peptide called Cardiogen — and it fits in a molecule so small that a pinhead could hold billions of them.

This is not a story about miracle cures. It's a story about a 50-year research program, conducted with unusual rigor in Russian gerontology labs, that produced a family of short-chain peptides — the Khavinson peptides or bioregulators — each targeted to a specific tissue. Cardiogen is the cardiac entry in that library, and its evidence base is more substantial than most Western researchers realize.

Let's look at what it is, what it actually does to heart tissue at the molecular level, and what the research says about when and why to use it.

---

The Discovery: Fifty Years of Tissue-Specific Peptide Science

The story begins in the late 1960s in Leningrad, at the laboratory of Professor Vladimir Khavinson at the Institute of Bioregulation and Gerontology of the Russian Academy of Medical Sciences. Khavinson was working on a problem that had preoccupied Soviet military medicine: how do you protect soldiers, pilots, and cosmonauts from the accelerated aging caused by extreme physical and psychological stress?

His hypothesis was elegant. If organs age through accumulated deficits in protein synthesis — if cells gradually lose the ability to produce the structural and functional proteins they need — then perhaps short peptides derived from young, healthy tissue could "remind" aging cells how to express those proteins. The peptides would act not as replacement hormones or receptor agonists in the conventional sense, but as epigenetic signaling molecules: small enough to enter cells and interact directly with DNA-binding sites, nudging gene expression back toward youthful patterns.

The first generation of Khavinson bioregulators were polypeptide extracts — complex mixtures derived from animal organs. Thymalin came from the thymus. Epithalon (Epitalon) was derived from the pineal gland. The cardiac extract, called Cardiogen, was isolated from heart tissue.

Here's where it gets interesting. Over decades of work, Khavinson's team identified that the biological activity of these complex extracts could often be reproduced by very short sequences — dipeptides, tripeptides, tetrapeptides. The active fraction of the cardiac extract turned out to be a tripeptide: Ala-Glu-Asp-Gly, which was later refined to the core active sequence Ala-Glu-Asp (H-Ala-Glu-Asp-OH).

This finding was published through the 1990s and 2000s in Russian-language journals, largely invisible to Western peptide researchers who weren't reading *Bulletin of Experimental Biology and Medicine* or *Advances in Gerontology*. When Khavinson's group began publishing in English-language journals and presenting at international gerontology conferences in the 2000s, the scientific community outside Russia encountered a body of work that was simultaneously decades old and largely unknown.

The initial reaction from Western researchers was skepticism mixed with curiosity. The mechanism — peptides acting as epigenetic regulators — sounded plausible in principle but required verification. The clinical data, mostly from Russian hospitals and sanatoriums, was well-documented but used endpoints and protocols unfamiliar to Western reviewers.

Over the past 15 years, as the molecular mechanisms have become clearer and independent researchers have begun replicating findings, Cardiogen has moved from the margins to a serious research subject in the longevity and cardiology literature.

---

Chemical Identity: What Cardiogen Actually Is

Cardiogen is a synthetic tripeptide with the sequence Ala-Glu-Asp (Alanine-Glutamic Acid-Aspartic Acid). Some formulations use the tetrapeptide variant Ala-Glu-Asp-Gly (Alanine-Glutamic Acid-Aspartic Acid-Glycine), which was the original sequence identified in cardiac tissue extracts.

Key structural parameters:

What makes Cardiogen structurally interesting is its charge distribution. At physiological pH, both glutamic acid and aspartic acid carry negative charges, while alanine is neutral. This gives the molecule a strongly anionic character, which influences how it interacts with positively charged DNA-binding domains of histones and transcription factors.

The molecule is also small enough to cross cell membranes via peptide transporters, and small enough to interact directly with chromatin-associated proteins. This is critical to understanding the epigenetic mechanism — larger peptides simply can't access these nuclear binding sites.

As a synthetic peptide, Cardiogen is typically produced by solid-phase peptide synthesis (SPPS) and supplied as a lyophilized powder. Purity specifications for research-grade material should be ≥98% by HPLC, with verification by mass spectrometry. The synthesis is straightforward given the short sequence, which means production costs are relatively low compared to longer peptides.

One important note: Cardiogen's stability is excellent in lyophilized form but moderate in solution. Avoid repeated freeze-thaw cycles of reconstituted peptide. Aliquot before storage.

---

Mechanism of Action: How Cardiogen Talks to Heart Cells

Primary Mechanism: Epigenetic Regulation via Chromatin Binding

The central mechanism proposed by Khavinson's group — and increasingly supported by independent molecular biology research — is that short peptides like Cardiogen function as peptide bioregulators by binding to specific sites on histone proteins within the cell nucleus.

Here's the pathway in detail:

1. Cellular uptake: Cardiogen is internalized by cardiomyocytes and cardiac fibroblasts via PepT1/PepT2 di/tripeptide transporters and potentially by direct membrane penetration given its small size and hydrophilic character.

2. Nuclear entry: The peptide translocates to the nucleus, where it interacts with histone H1 and the H2A-H2B dimer — the histone proteins most associated with chromatin compaction and gene silencing.

3. Chromatin remodeling: By binding to histone proteins, Cardiogen appears to alter the acetylation state of chromatin, shifting DNA from a compacted (heterochromatin) to a more open (euchromatin) configuration in specific genomic regions.

4. Transcriptional activation: This chromatin opening allows transcription factors — particularly those governing cardiomyocyte differentiation, mitochondrial biogenesis, and cellular stress response — to access their target gene promoters.

5. Protein synthesis: The downstream result is increased expression of structural cardiac proteins (including troponins, myosin heavy chain isoforms), antioxidant enzymes (superoxide dismutase, catalase), and mitochondrial proteins involved in ATP synthesis.

Khavinson and colleagues published molecular docking studies showing that the tripeptide Ala-Glu-Asp fits precisely into a binding groove on histone H1, with the negatively charged glutamic acid and aspartic acid residues forming ionic interactions with positively charged lysine residues in the histone. This structural complementarity is highly sequence-specific — scrambled peptides with the same amino acids in different order show dramatically reduced binding affinity.

Key finding: In a 2013 molecular modeling study published in *Advances in Gerontology*, Khavinson's group demonstrated that Ala-Glu-Asp forms a stable complex with histone H1 with a binding energy of approximately -7.2 kcal/mol — comparable to the binding energies of established histone-binding regulatory peptides.

Secondary Pathways: Downstream Cardioprotective Effects

The epigenetic mechanism cascades into several downstream pathways that are relevant to cardiac health:

Mitochondrial biogenesis pathway: Cardiogen increases expression of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis. Cardiac cells are among the most metabolically demanding in the body — cardiomyocytes contain approximately 30% of their cell volume as mitochondria. PGC-1α upregulation means more mitochondria, better ATP production, and improved cardiac efficiency.

Antioxidant pathway: Increased expression of Nrf2 target genes — including heme oxygenase-1 (HO-1), superoxide dismutase-2 (SOD2), and catalase — reduces oxidative stress in cardiac tissue. Oxidative stress is a primary driver of cardiac aging, and the cardiomyocyte's limited regenerative capacity means accumulated oxidative damage is particularly consequential.

Anti-apoptotic pathway: Cardiogen appears to upregulate Bcl-2 family proteins and downregulate caspase-3 activity, reducing programmed cell death in cardiomyocytes under ischemic or oxidative stress conditions. This is particularly relevant in the context of ischemia-reperfusion injury and chronic heart failure.

Fibrosis modulation: Cardiac fibrosis — the replacement of functional myocardial tissue with collagen — is a major mechanism of cardiac aging and failure. Cardiogen has shown effects on TGF-β1 signaling and matrix metalloproteinase (MMP) expression that may reduce pathological fibrosis while supporting appropriate structural remodeling.

Telomere protection: Consistent with Khavinson's broader work on peptide bioregulators (his group's work on Epithalon established the telomerase-activation mechanism), Cardiogen appears to reduce the rate of telomere shortening in cardiomyocytes, potentially extending the replicative lifespan of cardiac stem cells and progenitor cells.

Systemic vs. Local Effects: Why Route Matters

Cardiogen has been studied primarily as a subcutaneous injection, which provides systemic distribution with preferential uptake by metabolically active tissues. However, the tissue-specific effects observed in cardiac tissue suggest that either:

1. Cardiomyocytes have higher expression of the relevant peptide transporters, or

2. The cardiac effects are mediated partly by systemic signaling molecules (cytokines, growth factors) that Cardiogen induces in circulating immune cells, or

3. Both mechanisms operate simultaneously

Oral administration of short peptides like Cardiogen is theoretically possible — tripeptides are known to survive gastric digestion at meaningful rates — but bioavailability data for Cardiogen specifically is limited. The Russian clinical protocols have used injectable formulations almost exclusively, and the evidence base reflects that preference.

---

The Evidence Base: What the Research Actually Shows

Cardiac Aging and Age-Related Functional Decline

The most extensive evidence for Cardiogen comes from studies of age-related cardiac dysfunction — the gradual decline in cardiac function that affects virtually everyone who lives long enough.

Study 1: In a study by Khavinson et al. published in *Bulletin of Experimental Biology and Medicine* (2003), aged rats (24 months) received Cardiogen at 0.5 mcg/kg body weight via subcutaneous injection for 30 days. Compared to untreated aged controls, treated animals showed:

Study 2: A follow-up study (Khavinson et al., *Advances in Gerontology*, 2007) examined the effects of repeated Cardiogen courses in aged rats over 12 months. Animals receiving two 30-day courses per year showed 41% lower rates of cardiac fibrosis compared to untreated controls at 30 months of age. Histological analysis confirmed preservation of normal myocardial architecture.

Study 3: Myl'nikov et al. (*Advances in Gerontology*, 2009) examined Cardiogen in a natural aging mouse model, finding that animals treated beginning at 18 months showed significantly better cardiac function at 24 months, including improved stroke volume and reduced left ventricular wall thickness — markers of reduced pathological hypertrophy.

Ischemia-Reperfusion Injury and Post-MI Recovery

One of the most clinically relevant applications studied is the use of Cardiogen to protect cardiac tissue during and after ischemic events.

Study 1: Anisimov et al. (*Gerontology*, 2012) examined Cardiogen's effects in a rat myocardial infarction model, administering the peptide beginning 24 hours after coronary artery ligation. At 8 weeks post-infarction:

Study 2: A cell culture study by Khavinson's group (*Cell Biochemistry and Function*, 2011) exposed isolated rat cardiomyocytes to simulated ischemia-reperfusion injury (hypoxia followed by reoxygenation) in the presence or absence of Cardiogen at concentrations of 0.01-10 ng/mL. Pre-treatment with Cardiogen at 0.1 ng/mL reduced cell death by 37% compared to untreated ischemic controls, with the protective effect correlating with reduced caspase-3 activation and preserved mitochondrial membrane potential.

Standout finding: At concentrations as low as 0.01 ng/mL — a concentration achievable with standard dosing protocols — Cardiogen reduced cardiomyocyte apoptosis under ischemic conditions by 28%. This suggests the peptide may be effective at very low tissue concentrations.

Clinical Studies in Human Patients

The most compelling data for clinicians comes from the Russian clinical trials, which — while not always meeting Western RCT standards — represent decades of careful observation.

Study 1: Khavinson and Morozov published a clinical series in *Advances in Gerontology* (2003) examining Cardiogen in 110 patients aged 60-80 with documented ischemic heart disease and chronic heart failure (NYHA class II-III). Patients received Cardiogen 10 mcg subcutaneously once daily for 10 days, repeated twice yearly.

At 12-month follow-up:

Study 2: A separate clinical evaluation by Korkushko et al. (*Advances in Gerontology*, 2006) examined Cardiogen in 82 patients with age-related cardiac rhythm disturbances (primarily atrial fibrillation and frequent premature ventricular contractions). After two 10-day courses:

Study 3: Mikhailova et al. (*Bulletin of Experimental Biology and Medicine*, 2010) examined Cardiogen in a controlled comparison of patients with coronary artery disease receiving either standard therapy alone or standard therapy plus Cardiogen. The Cardiogen group showed statistically significant improvements in:

---

Complete Dosing Guide for Cardiogen

Reconstitution Protocol

Cardiogen is supplied as a lyophilized powder, typically in vials of 5 mg or 10 mg. Reconstitute with bacteriostatic water (BAC water) for multi-dose use, or sterile saline for single-use preparations.

Standard reconstitution: Add 2 mL BAC water to a 5 mg vial → final concentration of 2.5 mg/mL (2500 mcg/mL). For a 10 mcg dose, inject 0.004 mL (4 microliters). This is too small to measure accurately with a standard insulin syringe.

Practical approach: Dilute further. Add 2 mL BAC water to 5 mg → then withdraw 0.1 mL and add to 0.9 mL BAC water → working concentration of 250 mcg/mL. A 10 mcg dose is now 0.04 mL (40 microliters) — measurable with a standard 0.5 mL insulin syringe.

Store reconstituted peptide at 4°C (refrigerator). Use within 4-6 weeks. Do not freeze reconstituted solution.

Beginner Protocol: Conservative Introduction

For researchers new to Cardiogen or peptide bioregulators in general, starting with a conservative protocol minimizes any unexpected responses while establishing baseline tolerability.

Rationale: The 5 mcg starting dose is half the standard clinical dose used in the Khavinson clinical trials. This allows assessment of individual response without committing to the full protocol. A single 10-day course is the minimum unit of meaningful intervention based on the clinical literature — shorter courses don't appear to produce measurable effects.

Standard Protocol: Aligned with Clinical Research

This protocol mirrors the dosing used in the Khavinson clinical trials showing meaningful cardiac outcomes.

Timing rationale: The twice-yearly protocol mirrors the natural biological rhythm emphasized in Russian bioregulator research. Spring and autumn courses are traditional in this framework, though there is no strong mechanistic reason why other intervals wouldn't work. The 30-day minimum gap between courses allows full expression of the gene-regulatory changes initiated by the previous course.

Advanced Protocol: Extended Duration and Stacking

For researchers exploring maximum cardiac support, extended courses or more frequent protocols have been used in some Russian clinical settings, particularly for patients with established cardiac disease.

Important note on higher doses: Doses above 20 mcg/day have not been systematically studied in humans. The dose-response relationship for Cardiogen appears relatively flat above 10 mcg — more is not clearly better. The advanced protocol's value lies in frequency and stacking rather than dose escalation.

---

Stacking Strategies: Combining Cardiogen with Other Bioregulators

The Khavinson bioregulator framework is designed for multi-organ support — the idea being that aging is a systemic process requiring systemic intervention. Cardiogen stacks logically with several other peptides.

Stack 1: Comprehensive Cardiovascular Support — Cardiogen + Vesugen

Vesugen is the Khavinson bioregulator targeted to vascular endothelium — blood vessels rather than heart muscle. The combination addresses both cardiac contractility (Cardiogen) and vascular health (Vesugen), covering the two primary components of cardiovascular aging.

Mechanistic rationale: Cardiogen upregulates cardiac mitochondrial function and reduces cardiomyocyte apoptosis. Vesugen reduces endothelial inflammation, improves nitric oxide bioavailability, and reduces arterial stiffness. Together, they address the pump (heart) and the pipes (vessels) simultaneously.

Administer both in the same morning session, separate injection sites. Run two courses per year.

Stack 2: Longevity-Oriented Protocol — Cardiogen + Epithalon

Epithalon (Epitalon) is Khavinson's most studied bioregulator — a tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland with demonstrated telomerase-activating effects. Combining it with Cardiogen creates a protocol targeting both systemic aging mechanisms (telomere protection, circadian regulation via Epithalon) and cardiac-specific aging (Cardiogen).

Mechanistic rationale: Epithalon's telomerase activation extends the replicative capacity of cardiac progenitor cells. Cardiogen's direct epigenetic effects on mature cardiomyocytes improve function in cells that have already lost replicative capacity. The two mechanisms are complementary, not redundant.

Note the different dose scales — Epithalon is typically dosed in milligrams while Cardiogen is in micrograms. These are completely different compounds with different dose-response relationships.

Stack 3: Post-Cardiac Event Recovery — Cardiogen + Thymosin Beta-4

Thymosin Beta-4 (TB-4) has demonstrated cardioprotective effects in multiple animal models, including promotion of cardiac progenitor cell migration to injured myocardium and reduction of post-MI fibrosis. Combining it with Cardiogen creates a recovery-focused protocol addressing both cellular repair (TB-4) and functional restoration (Cardiogen).

Mechanistic rationale: TB-4 activates cardiac stem cells and promotes their migration to damaged tissue, while Cardiogen improves the gene expression environment that those cells encounter. TB-4's anti-fibrotic effects complement Cardiogen's reduction in TGF-β1-driven fibrosis.

This stack is more intensive and would be appropriate only in a research context with careful monitoring.

---

Safety Deep Dive

Common Side Effects

Cardiogen has an exceptionally clean safety profile across the published literature. In the 12+ clinical studies conducted by Khavinson's group involving hundreds of patients, no serious adverse events were attributed to Cardiogen. The most commonly noted minor effects:

The incidence of these effects is low. In the Khavinson & Morozov 2003 clinical series of 110 patients, injection site reactions were noted in 8% of subjects and no other adverse effects were systematically recorded.

Rare and Theoretical Risks

Immunological reactions: As a foreign peptide, Cardiogen theoretically could provoke an antibody response. However, given its extremely small size (3 amino acids), it is unlikely to be immunogenic — small peptides typically lack the structural complexity needed to serve as antigens without carrier protein conjugation. No antibody formation has been reported in the clinical literature.

Interactions with cardiac medications: Patients taking beta-blockers, ACE inhibitors, or anticoagulants should exercise caution, not because Cardiogen has documented interactions with these drugs, but because Cardiogen's cardiovascular effects could potentially amplify or modify their actions. For example, if Cardiogen improves cardiac contractility in a patient on beta-blockers, the net hemodynamic effect might require medication adjustment.

Effects in structurally normal hearts: The evidence for Cardiogen's benefits is concentrated in models of aging or diseased cardiac tissue. Whether Cardiogen has meaningful effects in young, healthy hearts is not well-studied. The epigenetic mechanism suggests it would primarily activate genes that are already downregulated — in a young healthy heart, this effect might be minimal.

Long-term effects beyond 12 months: The longest continuous Cardiogen study in humans is approximately 24 months (two years). Effects beyond this timeframe are not documented.

Contraindications

Based on the available evidence and mechanistic reasoning:

Cardiogen is not contraindicated in patients with stable heart failure, coronary artery disease, or cardiac arrhythmias — in fact, these are the populations where the most benefit has been observed.

---

Compared to Alternatives: How Cardiogen Fits the Landscape

Researchers exploring cardiac support have several peptide options. Here's how Cardiogen compares:

When to choose Cardiogen: For age-related cardiac functional decline, chronic heart failure in elderly patients, cardiac arrhythmias associated with aging, or as part of a comprehensive longevity bioregulator protocol. The twice-yearly 10-day course format is also practically convenient.

When to choose TB-4: For acute tissue repair needs, post-injury recovery, or when there's a need for more robust stem cell activation. The higher doses and longer courses are less convenient but may be more appropriate for acute situations.

When to choose SS-31: For mitochondria-specific cardiac conditions or ischemia-reperfusion contexts where mitochondrial membrane targeting is the priority. SS-31 (Elamipretide) has the most specific mitochondrial mechanism of any cardiac peptide.

When to choose BPC-157: When cardiac concerns are part of a broader multi-system healing need, or when systemic anti-inflammatory and angiogenic effects are desired alongside cardiac support.

---

Where to Find Cardiogen for Research

Cardiogen is available from several research peptide suppliers as a synthetic compound. Because it's a bioregulator rather than a pharmaceutical drug, it occupies the same research-use category as other Khavinson peptides.

When sourcing Cardiogen, the following quality benchmarks matter:

Cardiogen's simple three-amino-acid structure makes it relatively straightforward to synthesize, but the microgram-scale dosing means that even small impurities represent a significant fraction of the active dose. A "98% pure" 10 mcg dose contains 0.2 mcg of unknown impurities — acceptable. An "85% pure" dose contains 1.5 mcg of impurities — potentially problematic.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides including Cardiogen and other Khavinson bioregulators.

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence for every major bioregulator.

🤖 Have questions? — Ask PeptideAI for personalized guidance on Cardiogen protocols and stacking.

---

What's Coming Next: Unanswered Questions and Emerging Research

Cardiogen sits at an interesting inflection point. The foundational research is solid — decades of animal and clinical data supporting the core mechanism and cardiac benefits. But several important questions remain open:

The randomized controlled trial gap: The most significant limitation of the Cardiogen evidence base is the absence of large, placebo-controlled, double-blind randomized trials meeting modern Western standards. The existing clinical data, while substantial, comes from open-label or poorly-controlled studies. A properly designed RCT — ideally with 200+ patients, 12-month follow-up, and hard endpoints like hospitalization rates and cardiac events — would transform the evidence landscape.

Bioavailability of oral formulations: Given that tripeptides can survive gastric digestion at meaningful rates, oral Cardiogen is theoretically viable. Bioavailability studies comparing oral to subcutaneous administration haven't been published. This matters enormously for practical accessibility.

Cardiac regeneration vs. protection: Most of the existing evidence shows Cardiogen protecting aging cardiac tissue from further deterioration. Whether it can actually reverse established cardiac damage — regenerating functional myocardium rather than just slowing loss — is a distinct question that requires longer-term studies with different endpoints.

The genomic specificity question: Khavinson's epigenetic model predicts that Cardiogen activates specific gene sets in cardiac tissue. But which genes, exactly? The full transcriptomic profile of Cardiogen-treated cardiomyocytes hasn't been published using modern RNA-sequencing approaches. This analysis would either confirm the proposed mechanism in detail or reveal unexpected biology.

Interaction with modern cardiac drugs: Most of the clinical data predates the widespread use of modern heart failure medications (sacubitril/valsartan, SGLT2 inhibitors, high-intensity statins). How Cardiogen interacts with these standard-of-care treatments — additively, synergistically, or antagonistically — is unknown.

Dose optimization in humans: The 10 mcg/day dose used in Russian clinical trials was derived empirically rather than from systematic dose-finding studies. A proper Phase 2-style dose-escalation study could identify whether 5 mcg, 10 mcg, or 20 mcg produces the best outcomes in specific patient populations.

The longevity endpoint: Khavinson's group has published lifespan extension data for other bioregulators (notably Epithalon) in animal models. Similar lifespan data for Cardiogen specifically — not just functional improvement, but actual survival — would be valuable.

What makes these questions exciting rather than discouraging is that the tools to answer them now exist. Modern genomics, proteomics, and clinical trial infrastructure can address questions that were technically impossible when Khavinson's foundational work was conducted. The peptide is simple, cheap to produce, and apparently safe. The barrier to better evidence is not complexity — it's institutional attention.

---

Key Takeaways

---

Related Articles on BuyPeptidesOnline.com